1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with 1-naphthylisothiocyanate in 1 studies
| Studies (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Trials (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Recent Studies (post-2010) (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Studies (1-naphthylisothiocyanate) | Trials (1-naphthylisothiocyanate) | Recent Studies (post-2010) (1-naphthylisothiocyanate) |
|---|---|---|---|---|---|
| 9,156 | 187 | 552 | 414 | 0 | 142 |
| Protein | Taxonomy | 1-hexadecyl-2-acetyl-glycero-3-phosphocholine (IC50) | 1-naphthylisothiocyanate (IC50) |
|---|---|---|---|
| Cytochrome P450 1A2 | Homo sapiens (human) | 1 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 6.272 | |
| Adenosine receptor A3 | Homo sapiens (human) | 6.1 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 6.1 | |
| C-C chemokine receptor type 2 | Homo sapiens (human) | 6.699 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 6.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bailie, MB; Fink, GD; Pearson, JM; Roth, RA | 1 |
1 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and 1-naphthylisothiocyanate
| Article | Year |
|---|---|
Platelet activating factor receptor blockade alone or in combination with leukotriene synthesis inhibition does not ameliorate alpha-naphthylisothiocyanate-induced hepatotoxicity.
Topics: 1-Naphthylisothiocyanate; Animals; Azepines; Hydroxyurea; Leukotrienes; Lipoxygenase Inhibitors; Liver; Male; Platelet Activating Factor; Rats; Rats, Sprague-Dawley; Triazoles | 1996 |